PMID- 17187505
OWN - NLM
STAT- MEDLINE
DCOM- 20071203
LR  - 20061225
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 8
IP  - 1
DP  - 2007 Jan
TI  - Cardiovascular therapy and pharmacogenetics in 2007.
PG  - 21-3
AB  - John Carlquist received a PhD from the Department of Cellular Viral and Molecular 
      Biology at the University of Utah School of Medicine (UT, USA) with research 
      emphasis in molecular immunology. After completion of his training, he received a 
      faculty appointment in the Department of Internal Medicine, University of Utah, 
      where he became interested in immune mechanisms in cardiovascular disease. He 
      developed an interest in genetics through studies of human leukocyte antigen 
      (HLA) associations with idiopathic dilated cardiomyopathy and rheumatic heart 
      disease. He began the Molecular Diagnostics Laboratory for Intermountain 
      Healthcare and continues to serve as Technical Director; he also directs the 
      Intermountain Heart Study Molecular and Genetic Research Laboratory. Current 
      research interests include the genetics of lipid metabolism as related to 
      coronary heart disease and the genetic factors influencing drug treatment 
      outcomes.
FAU - Carlquist, John
AU  - Carlquist J
LA  - eng
PT  - Interview
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Cardiovascular Agents/administration & dosage
MH  - Cardiovascular Diseases/drug therapy/*genetics
MH  - Genetic Markers
MH  - Humans
MH  - Life Style
MH  - Pharmacogenetics/methods/*trends
EDAT- 2006/12/26 09:00
MHDA- 2007/12/06 09:00
CRDT- 2006/12/26 09:00
PHST- 2006/12/26 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2006/12/26 09:00 [entrez]
AID - 10.2217/14622416.8.1.21 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2007 Jan;8(1):21-3. doi: 10.2217/14622416.8.1.21.